Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.58% -0.11% 274.40M 6081.00
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 252.0% -14.17M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Invesco
Prospectus Benchmark Index
Dynamic Biotech&Genome Intellidex TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Peter Hubbard 13.93 yrs
Michael Jeanette 12.68 yrs
Tony Seisser 6.68 yrs
Pratik Doshi 0.67 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 57
-14.17M
-4.429B Category Low
8.106B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of April 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of May 07, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
2.31%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
11.38%
--
--
--
--
--
--
65.01%
3.02%
31.16%
5.70%
-19.53%
25.44%
-14.41%
25.51%
23.80%
2.20%
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
-3.66%
--
--
-25.62%
13.57%
-20.62%
24.19%
36.52%
-5.79%
As of May 07, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-7-21) 0.00%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 27.09
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 06, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 06, 2021

Asset Allocation

As of May 06, 2021.
Type % Net % Long % Short
Cash 0.04% Upgrade Upgrade
Stock 99.96% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Bio-Techne Corp 6.20% 423.05 2.94%
Alexion Pharmaceuticals Inc 6.09% 170.43 0.34%
Amgen Inc 6.08% 254.21 1.16%
Biomarin Pharmaceutical Inc 5.29% 77.77 -1.07%
Qiagen NV 5.22% 47.64 -0.15%
Catalent Inc 5.21% 107.56 1.30%
Seagen Inc Ordinary Shares 4.99% 139.49 2.51%
Illumina Inc 4.66% 383.94 1.82%
Ironwood Pharmaceuticals Inc Class A 3.49% 10.98 4.62%
Intellia Therapeutics Inc 3.47% 67.74 1.90%

News

Headline
Wire
Time (ET)
SA Breaking News
08/26 11:01
SA Breaking News
06/17 13:21
SA Breaking News
01/02 04:34
SA Breaking News
10/25 14:32
SA Breaking News
06/22 12:07
SA Breaking News
06/01 15:48
SA Breaking News
05/30 13:50
SA Breaking News
12/29 08:03

Basic Info

Investment Strategy
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Invesco
Prospectus Benchmark Index
Dynamic Biotech&Genome Intellidex TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Peter Hubbard 13.93 yrs
Michael Jeanette 12.68 yrs
Tony Seisser 6.68 yrs
Pratik Doshi 0.67 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-7-21) 0.00%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 27.09
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 06, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 06, 2021

Fund Details

Key Dates
Inception Date 6/23/2005
Last Annual Report Date 4/30/2020
Last Prospectus Date 8/28/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Headline
Wire
Time (ET)
SA Breaking News
08/26 11:01
SA Breaking News
06/17 13:21
SA Breaking News
01/02 04:34
SA Breaking News
10/25 14:32
SA Breaking News
06/22 12:07
SA Breaking News
06/01 15:48
SA Breaking News
05/30 13:50
SA Breaking News
12/29 08:03